Phthalocyanins, Production Processes and Uses

Description

1 / 13 Phthalocyanins, Production Processes and Uses Technical Field of the Invention

[0001] This patent application discloses new compounds derived from phthalocyanines, their production processes and related uses. Summary of the Invention

[0002] This patent application presents a new group of compounds defined as adducts or supramolecular complexes between species belonging to the guanidine group with iron and / or cobalt octacarboxyphthalocyanine acids. These molecular associations result in new entities that possess low toxicity and surprising stability to self-degradation in aqueous solutions of neutral pH to slightly alkaline medium (6 < pH < 9).

[0003] In an embodiment of the present patent application, the aforementioned compounds are effective as antiseptic agents and / or in inactivating microorganisms, such as viruses or bacteria. Additionally, they can act as wound healing compounds.

[0004] In a preferred embodiment, the aforementioned compounds are effective against respiratory viruses, including enveloped viruses such as influenza, herpes, monkeypox (MPX), RSV, and coronaviruses such as SARS-CoV-2.

[0005] In an embodiment of the present patent application, the said compound can be prepared in different types of formulations such as tinctures, suspensions, gels, pastes and creams, especially aqueous solutions and dispersions. Description of the Figures

[0006] Figure 1: UV-vis spectrum of the guanidinitic compound iron phthalocyanine octacarboxylate in 0.1 mol.L⁻¹ sodium hydroxide solution.

[0007] Figure 2: Infrared spectrum of the guanidinitic iron phthalocyanine octacarboxylate compound obtained by the ATR technique.

[0008] Figure 3: Elemental analysis of the guanidinix compound of Petition 870250076037, dated 08 / 27 / 2025, page 6 / 26 2 / 13 iron phthalocyanine octacarboxylate.

[0009] Figure 4: Thermogravimetric curve of the guanidine compound of iron phthalocyanine octacarboxylate.

[0010] Figure 5: Comparison of the mouthwash formulations with guanidine compound iron phthalocyanine octacarboxylate (left) and iron phthalocyanine octacarboxylic acid (i.e., in its protonated form) (right) after 120 days. Initially, both solutions had the same color. Detailed Description of the Invention

[0011] The present detailed description of the invention establishes some, non-limiting, definitions of the main terminologies and technical characteristics employed throughout this patent application, as well as providing examples of some embodiments of the present invention so that it can be reproduced by a person skilled in the art.

[0012] In one embodiment of the present invention, said compounds have the general formula I: (X'm) (XV) Γ* C (X+m) -O y o-(xn.m)where M = transition metal ion, which may be selected for example. Petition 870250076037, dated 08 / 27 / 2025, p. 7 / 26 3 / 13 between Fe or Co; Peripheral cations defined as (Xn+m) are species belonging to the group defined as: They can be selected from guanidine (R = Ri = R2 = Rs = H), arginine (R = Ri = R2 = H; R3 = CH2CH2CH2C(NH2)COOH), creatine (R = CH3; Ri = R2 = H; R3 = CH2COOH), creatinine (Ri = C(O)CH2-R; R2 = H; Rs = CH3), guanidinoacetate (R = Ri = R2 = H; R3 = CH2COOH), biguanide (R = Ri = R2 = H; R3 = C(NH)NH2), metformin (R = Ri = R2 = H; R3 = C(NH)N(CH3)2), chlorhexidine, or a combination thereof; and; (Xn+m) can be present in the structure from 1 to 8 repetitions in the chemical formula described above. Furthermore, men can vary between 1 and 2. In a preferred embodiment, m=1 if n=2, or, if m=2 if n=1.

[0013] In one embodiment of the present invention, said compounds may be present in a composition having general formula II: Petition 870250076037, dated 08 / 27 / 2025, page 8 / 26 4 / 13 where M = transition metal ion, which can be selected, for example, from Fe and Co; Y and Z represent axial ligands (any coordinating molecules present in the reaction medium) and can be selected, for example, from water, acetate, chloride, ammonia, hydroxyl, or a combination thereof; The peripheral cations defined as (Xn+m) are species belonging to the group defined as: H R2 or r3 I N o They can be selected from guanidine (R = Ri = R2 = Rs = H), arginine (R = Ri = R2 = H; R3 = CH2CH2CH2C(NH2)COOH), creatine (R = CH3; Ri = R2 = H; R3 = CH2COOH), creatinine (Ri = C(O)CH2-R; R2 = H; Rs = CH3), guanidinoacetate (R = Ri = R2 = H; R3 = CH2COOH), biguanide (R = Ri = R2 = H; R3 = C(NH)NH2), metformin (R = Ri = R2 = H; R3 = C(NH)N(CH3)2), chlorhexidine, or a combination thereof; and; (Xn+m) can be present in the structure from 1 to 8 repetitions in the chemical formula described above. Furthermore, men can vary between 1 and 2. In a preferred embodiment, m=1 if n=2, or, m=2 if n=1.

[0014] Preparation and characterization procedures for the compounds of the present invention

[0015] To prepare the supramolecular compound, 4.6 g of iron octacarboxylic phthalocyanine acid (which can be prepared by various processes, for example, as described in patent BR102016023307) were added to 40 g of water containing 2.5 g of ammonium hydroxide. Then, 4.78 g of guanidine hydrochloride dissolved in 10 g of water were added to the solution containing the phthalocyanine and heated to 80 °C for 60 min. The volume was reduced by half by distillation, resulting in a green solution. Petition 870250076037, dated 08 / 27 / 2025, page 9 / 26 5 / 13 dark liquid was added to 50 g of ethanol. The precipitate was isolated by filtration, air-dried, and oven-dried at 120 °C. The compound was characterized by UV-vis spectroscopy (Figure 1), infrared spectroscopy (Figure 2), elemental analysis (Figure 3), and thermogravimetry (Figure 4).

[0016] In one embodiment of the present invention, the empirical molecular formula obtained for the compound C44H4iFeN2iOi7. (n= 4) is:

[0017] Guanidinium iron octacarboxylate phthalocyanine (guanidinium iron octacarboxylate phthalocyanine) in aqueous solution exhibited high efficacy against the SARS-CoV-2 virus.

[0018] Guanidinium iron octacarboxylate phthalocyanine in aqueous solution showed high efficacy against SARS-CoV-2 virus variant Omicron strain XBB.1.16 (Arcturus). The experiments were carried out in the BSL3 Laboratory (Biosafety Level 3) of the Microbiology Department of the Institute of Biomedical Sciences of the University of São Paulo, which follows all the Petition 870250076037, dated 08 / 27 / 2025, page 10 / 26 This experiment complies with WHO (World Health Organization) Biosafety standards and Good Laboratory Practices (GLP). Vero CCL-81 and MDCK cell cultures were seeded at a rate of 1x10⁵ cells / well in a 24-well plate, and SARS-CoV-2 Variant Omicron strain XBB.1.16 (Arcturus) was tested at a concentration of 1x10³ TCID₅₀ / mL. Based on observation of cytopathic effect, cytotoxicity, and comparison with Real-Time RT-PCR results, a 99.93% reduction in viral load was obtained for SARS-CoV-2 Variant Omicron strain XBB.1.16 (Arcturus), without any cytotoxic effect on the cell.

[0019] Guanidinium iron octacarboxylate phthalocyanine in aqueous solution showed high efficacy against Monkeypox virus.

[0020] The efficacy of guanidinium iron octacarboxylate phthalocyanine in aqueous solution showed high efficacy against Monkeypox MPXV virus (Genbank accession number ON751962.1). The experiments were performed in the BSL3 Laboratory (Biosafety Level 3) of the Microbiology Department of the Institute of Biomedical Sciences of the University of São Paulo, which follows all WHO - World Health Organization Biosafety standards and complies with Good Laboratory Practices (GLP). Vero CCL-81 and MDCK cell cultures, seeded at 1x10⁵ cells / well in a 24-well plate, and Monkeypox MPXV virus (Genbank accession number ON751962.1) were tested at a concentration of 1x10³TCID₅₀ / mL. Based on the observation of the cytopathic effect, cytotoxicity, and comparison of the results of Real-Time RT-PCR, we obtained a 99.74% reduction in viral load for the Monkeypox MPXV virus strain (Genbank accession number ON751962.1) without showing any cytotoxic effect on the cell.

[0021] Guanidinium iron octacarboxylate phthalocyanine in aqueous solution exhibited high efficacy against RSV virus, respiratory syncytial virus and human metapneumovirus.

[0022] Guanidinium iron phthalocyanine octacarboxylate in aqueous solution showed high efficacy against respiratory syncytial virus (RSV). This study evaluated the anti-RSV activity of guanidinium iron phthalocyanine octacarboxylate. Petition 870250076037, dated 08 / 27 / 2025, page 11 / 26 7 / 13 guanidinium in aqueous solution in in vitro and in vivo models. RSV strains (A and B) were isolated from children with associated symptoms. Cytotoxicity was assessed by the MTT colorimetric assay, and antiviral activity was evaluated by titration of the supernatant after incubation in the presence of the compound and RSV. RESULTS: To evaluate the cytotoxic potential of guanidinium iron phthalocyanine octacarboxylate in aqueous solution, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium reduction technique was used, which measures the metabolic viability of the cell. The cytotoxic activity test of the compound showed that the dose required to inhibit the viability of the cell monolayer by 50% was 5.43 ± 0.6 mg / mL (Figure 1A). It was also observed that, from a dose of 1.5 mg / mL, there was no statistical significance in relation to untreated cells. Determining the CC50 allowed us to select the concentrations to be tested for antiviral activity.To do this, monolayers were exposed to various concentrations of guanidinium iron phthalocyanine octacarboxylate diluted in DMEM medium and RSV subtype A (MOI 1), starting at 500 pg / mL, followed by incubation for 72 hours. The supernatants were then titrated. To investigate the compound's potential to act at the viral adsorption stage, the monolayer was incubated at 4 °C to make the cell membrane less fluid, which does not prevent adsorption but hinders penetration, followed by exposure to various concentrations of guanidinium iron phthalocyanine octacarboxylate in the presence of RSV. There was a drastic reduction in the viral titer of the supernatants in the presence of the compound throughout the incubation period (full time). At the highest concentration, inhibition was complete.It is possible to observe the total absence of cytopathic effect in the monolayer after 72 hours of infection at a concentration of 500 pg / mL and a significant reduction at concentrations of 125 and 31.2 pg / mL compared to the infected and untreated control. Surprisingly, in the adsorption inhibition assay (Entry), all concentrations tested were 100% effective in inhibiting viral infectivity. This result strongly supports the hypothesis that the action of guanidinium iron octacarboxylate phthalocyanine occurs in the first stage of the viral replicative cycle. The results show the high... Petition 870250076037, dated 08 / 27 / 2025, page 12 / 26 8 / 13 tolerance of HEp2 cells and the antiviral nature of the compound in the RSV A replicative cycle under in vitro conditions, with this molecule being able to significantly interfere with viral infectivity at concentrations well below the CC50 demonstrated in HEp-2 cells. Furthermore, in the investigation of the mechanism carried out so far, a potential for adsorption inhibition has been found, demonstrating that the compound may be effective in preventing infections. Further investigations of the in vitro mechanism, as well as evaluation in an in vivo model, will provide the necessary results to classify the antiviral activity of guanidinium iron octacarboxylate phthalocyanine in aqueous solution and possibly list the molecule as a candidate in the management of RSV.

[0023] Guanidinium iron octacarboxylate phthalocyanine in aqueous solution exhibited high efficacy against herpes viruses.

[0024] The efficacy of guanidinium iron octacarboxylate phthalocyanine in aqueous solution has demonstrated high efficacy against herpes viruses. Herpes simplex virus 1 (HSV-1) is a neurotropic viral agent transmitted by intimate contact, affecting mucocutaneous tissue such as the oral mucosa. In this study, we evaluated the anti-herpetic potential of guanidinium iron octacarboxylate phthalocyanine in aqueous solution. The results demonstrate a robust ability of the compound to inhibit infection in the model employed. Notably, the concentration required to inhibit cytopathic effects at an MOI of 2 was 75.8 times lower than the CC50 (4.7 pg / mL). Furthermore, a significant reduction in HSV-1 US3 gene expression was observed at an MOI of 0.01 with concentrations as low as 3.9 pg / mL.The activity of guanidinium iron octacarboxylate phthalocyanine in aqueous solution was also demonstrated in the absence of light, indicating that the compound functions independently of light exposure. Furthermore, this discovery raises questions about the potential light-mediated enhancement and the underlying mechanisms of the molecule's antiviral action. The release of reactive oxygen species suggests a potential virucidal mechanism involving direct destruction. Petition 870250076037, dated 08 / 27 / 2025, page 13 / 26 9 / 13 of the viral particle or essential components necessary for infectivity. Singlet oxygen is known to oxidize unsaturated bonds in lipids, leading to molecular destabilization. Given that HSV-1 is an enveloped virus, the saturation and subsequent destabilization of its lipid envelope may be responsible for the observed inhibition of infectivity. However, this hypothesis requires empirical validation.

[0025] The cream formulation incorporating guanidinium iron octacarboxylate phthalocyanine exhibited high stability and efficacy as an antiviral, antiseptic, and wound-healing agent.

[0026] The experiment was carried out in Laboratory NB-3 (Level of This experiment was conducted using Biosafety Level 3) of the Microbiology Department of the Institute of Biomedical Sciences at the University of São Paulo, which adheres to all WHO (World Health Organization) Biosafety standards and complies with Good Laboratory Practices (GLP). The experiment utilized Reconstructed Human Epidermis (SkinEthic™ RHE) from EPISKIN (Figure 1); Vero CCL-81 cell culture seeded 1x10⁵ cells / well in a 24-hole plate; SARS-CoV-2 virus / human / Bra / SP02cc / 2020 (GeneBank accession number MT350282) at a concentration of 1x10³TCID₅₀ / mL.

[0027] SkinEthic™ RHE cultures were received in the laboratory 24 hours before the experiment. Each transwell was removed from the solid medium, transferred to a 6-hole plate in liquid maintenance medium, and incubated at 37°C with a 5% CO2 atmosphere. On the same day, 24-hole plates with Vero CCL-81 cells were seeded and maintained at the same temperature and atmospheric conditions. Three different concentrations of guanidinium iron octacarboxylate phthalocyanine mixed with gel cream were analyzed (0.02%, 0.05%, and 0.25%) with three different exposure times (5 minutes, 30 minutes, and 60 minutes). Transwells containing SkinEthic™ RHE were treated with a gel layer, and after the time specified above, 30 µl of the viral solution were added. After 30 minutes, the supernatant was removed from the transwell and inoculated into the cell culture. After inoculation, the plate Petition 870250076037, dated 08 / 27 / 2025, page 14 / 26 The 10 / 13 plate was incubated for 30 minutes at 37°C with 5% CO2 for viral adsorption. After this period, the plates were observed under an optical microscope to verify the integrity of the cell carpet after adsorption, in order to determine the cytotoxicity of the tested product. The inoculum consisted of 200 µl of virus (1x10³TCID50 / mL) added to 270 µl of ligand solution and stored until real-time RT-PCR was performed. The wells were then filled with 600 µl of culture medium (DMEM) supplemented with 2.5% fetal bovine serum. The plate was incubated at 37°C with a 5% CO2 atmosphere for 72 hours in a humid chamber. After 72 hours of incubation, the plates were observed again under an optical microscope to verify the integrity of the cell carpet compared to the negative control. And to determine the inhibition of the cytopathic effect (morphological changes in the host cell caused by the inoculated virus) compared to the positive control.Immediately after microscopic analysis, 200 µl of supernatant were collected from each well and added to 270 µl of Binding Solution for Real-Time RT-PCR. After collection, the plate was fixed and stained with Naphtol Blue Black (Sigma-Aldrich).

[0028] Supernatants collected after 72 h were subjected to RealTime RT-PCR for SARS-CoV-2 virus detection. Genetic material extraction was performed using the NucliSENS® easyMag® ​​automated system (BioMerieux, Lyon, France), following the manufacturer's instructions. Viral RNA detection was performed using the AgPath-ID One-Step RT-PCR Kit (Applied Biosystems Inc., USA) on a 7500 Real-Time PCR machine (Applied Biosystems, Weiterstadt, Germany), according to protocol, primers, and probe for identification of the viral E gene (Corman et al., 2020).

[0029] Based on observation of the cytopathic effect, cytotoxicity and comparison of real-time RT-PCR results, we obtained the following percentages of SARS-CoV-2 virus inhibition: Cream 0.25% and 0.05% - 1 / 2 dilution - 100% viral reduction and: Cream 0.25% and 0.05% - 1 / 8 dilution - 100% viral reduction.

[0030] In a second experiment, the effectiveness of the antiseptic cream Petition 870250076037, dated 08 / 27 / 2025, page 15 / 26 A compound containing guanidinium iron phthalocyanine octacarboxylate as an antiseptic was tested against coronavirus b, leading to a reduction of more than 99% of the viral load at concentrations below 0.05% pg / mL. Guanidinium iron phthalocyanine octacarboxylate was described as having the ability to reduce COVID-19 symptoms 5, 6, 7, and 72 hours after infection using a mouthwash containing this compound. The effectiveness of a hand sanitizing cream with two different concentrations of the supramolecular compound (0.05% and 0.25%) and the duration of this effectiveness at five different time points (5 minutes, 1, 2, 3, and 4 hours) were also evaluated in Reconstructed Human Epidermis (SkinEthic™ RHE) from EPISKIN LTDA.In this study, we evaluated the antiviral capacity of a hand sanitizing cream with two different concentrations of guanidinium iron octacarboxylate phthalocyanine (0.05% and 0.25%) and the duration of this capacity at five different times (5 minutes, 1, 2, 3, and 4 hours) on Reconstructed Human Epidermis (SkinEthic™ RHE) from the company EPISKIN LTDA.

[0031] Guanidinium iron octacarboxylate phthalocyanine has shown high efficacy against INFLUENZA viruses.

[0032] Guanidinium iron octacarboxylate phthalocyanine in aqueous solution showed high efficacy against pandemic INFLUENZA A H1N1 virus, strain ICB - 2022 / 0042. The experiments were performed in the BSL3 Laboratory (Biosafety Level 3) of the Microbiology Department of the Institute of Biomedical Sciences of the University of São Paulo, which follows all WHO - World Health Organization Biosafety standards and complies with Good Laboratory Practices (GLP). Vero CCL-81 and MDCK cell cultures seeded at 1 x10⁵ cells / well in a 24-well plate and pandemic Influenza A H1N1 virus, strain ICB - 2022 / 0042, were tested at a concentration of 1x10³ TCID₅₀ / mL. Based on observation of the cytopathic effect, cytotoxicity, and comparison of real-time RT-PCR results, we obtained a 99.93% reduction in viral load for the H1N1 pandemic influenza A virus strain, ICB-2022 / 0042, and without... Petition 870250076037, dated 08 / 27 / 2025, page 16 / 26 12 / 13 exhibit cytotoxic effect on the cell.

[0033] Mouthwash formulations incorporating guanidinium iron phthalocyanine octacarboxylate exhibited high stability and efficacy as an antiviral antiseptic and wound healing agent.

[0034] In this study, the objective was to perform laboratory tests to evaluate the antiviral and cytotoxic properties of a mouthwash containing the compound. Our results, obtained by real-time RT-PCR, confirmed viral reduction with the use of the antiseptic mouthwash compared to the positive control used in the study in Vero CCL-81 cells. Based on the results obtained in this study, it was possible to assess that the antiseptic mouthwash with the compound was able to reduce the viral load when compared to the positive control at titers of 1:2 (99.96%), 1:4 (99.88%), 1:8 (99.84%), and 1:16 (92.65%), while partial viral neutralization was observed at titers of 1:32 (77.42%) and 1:64 (11.06%). No viral neutralization was observed below the titer of 1:128.

[0035] Formulations of guanidinium iron octacarboxylate phthalocyanine have shown high efficacy against microorganisms.

[0036] The efficacy of guanidinium iron octacarboxylate phthalocyanine as an antiseptic was tested against the following microorganisms: Staphylococcus aureus ATCC6538; Pseudomonas aeruginosa ATCC9027; Escherichia coli ATCC8739; Salmonella choleraesuis ATCC10708 and Leptospira biflexa (Patoc 1 strain), leading to a reduction of more than 99.98% at concentrations below 0.05% pg / mL. This study demonstrated the effectiveness of guanidinium iron octacarboxylate phthalocyanine in reducing microbial activity, particularly against the microorganisms Acinetobacter baumannii ATCC 19606, Candida auris CDBD 11903, and Clostridioides difficile ATCC 9689, with a reduction of up to 99.99% in the microbial load at application.In a Time Kill test conducted by ProLab Biotechnology to determine microbial effectiveness, a 99.98% reduction in viable microorganisms (Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Salmonella choleraesuis, and Candida albicans) was observed in the first 10 minutes (except...). Petition 870250076037, dated 08 / 27 / 2025, page 17 / 26 13 / 13 Candida albicans) and demonstrated efficacy in microbial reduction for 240 minutes, thus demonstrating satisfactory efficacy results for guanidinium iron octacarboxylate phthalocyanine. Based on the tests performed, we can observe that there was a 99.98% reduction in viable bacteria (Staphylococcus aureus; Pseudomonas aeruginosa; Escherichia coli; Salmonella Choleraesuis and Leptospira Biflexa).

[0037] Toothpaste / gel formulations incorporating guanidinium iron phthalocyanine octacarboxylate have exhibited high stability and efficacy as an antiviral antiseptic and wound healing agent.

[0038] Stable toothpaste gels and creams were prepared by dispersing guanidinium iron octacarboxylate phthalocyanine in standard formulations and tests were carried out indicating effectiveness in virus inactivation and also showed faster healing of wounds and canker sores, as well as improved bad odor.

[0039] Saline solution formulations incorporating guanidinium iron phthalocyanine octacarboxylate exhibited high stability and efficacy as an antiviral antiseptic and wound healing agent.

[0040] Also, stable formulations were made by dissolving guanidinium iron octacarboxylate phthalocyanine in water and saline, which when applied as a nasal or oral spray showed efficacy as an antiseptic and antiviral, with excellent acceptance, and also increased the speed of wound healing, suggesting antiseptic activity combined with action in the re-epithelialization process, accelerating the wound healing process.

[0041] The examples disclosed herein demonstrate only some of the embodiments and uses of the present invention. Alternative embodiments and variations of the invention may be devised by a person skilled in the art based on the technical knowledge described in this patent application and are defined from the claims set forth herein. Petition 870250076037, dated 08 / 27 / 2025, page 18 / 26

Claims

1 / 3 Claims 1. Octacarboxylate Metallophthalocyanine characterized by being of arginine, guanidine, biguanide, creatine, creatinine, guanidinoacetate, metformin and / or chlorhexidine.

2. Octacarboxylate Metallophthalocyanine, as well as its respective organoderivatives, including alkyl, acrylic and N-heterocyclic derivatives, characterized by comprising the general formula I: where M = transition metal ion; and; where R, R1, R2 and R3 can be individually H, alkyl substituents such as CH3, CH2CH2CH2C(NH2)COOH, CH2COOH, C(O)CH2-R, CH2COOH, C(NH)NH2, or C(NH)N(CH3)2; and where men can vary between 1 and 2. Petition 870250076037, dated 08 / 27 / 2025, page 19 / 26 2 / 3 3. Octacarboxylate Metallophthalocyanine, according to claim 2, characterized in that X is guanidine (R = R1 = R2 = R3 = H), arginine (R = R1 = R2 = H; R3 = CH2CH2CH2C(NH2)COOH), creatine (R = CH3; R1 = R2 = H; R3 = CH2COOH), creatinine (R1 = C(O)CH2-R; R2 = H; R3 = CH3), guanidinoacetate (R = R1 = R2 = H; R3 = CH2COOH), biguanide (R = R1 = R2 = H; R3 = C(NH)NH2), metformin (R = R1 = R2 = H; R3 = C(NH)N(CH3)2), or a combination thereof.

4. Octacarboxylate Metallophthalocyanine, according to claim 2, characterized in that m=1, n=2, or, if m=2 if n=1.

5. Octacarboxylate Metallophthalocyanine, according to claim 2, characterized in that M = transition metal ion selected from Fe or Co.

6. Composition, characterized by comprising one or more Metallophthalocyanine Octacarboxylate compounds as defined in any of claims 1 to 5 and further comprising at least one excipient, wherein the Metallophthalocyanine Octacarboxylate comprises General Formula II: Y and Z represent axial ligands of coordinating molecules present in the reaction medium.

7. Composition according to claim 6, characterized in that Y and Z (Petition 870250076037, dated 08 / 27 / 2025, page 20 / 26 3 / 3) are selected from molecules of water, acetate, chloride, ammonia, hydroxyl or a combination thereof.

8. Formulation, characterized by comprising at least one compound as defined in any one of claims 1 to 5 or at least one composition as defined in claim 6 or 7 prepared in the form of a suspension, gel, ointment, cream, tincture, solution or dispersion.

9. Use of at least one compound as defined in any of claims 1 to 5, or at least one composition as defined in claims 6 or 10, characterized by being for the production of an antiseptic, wound-healing composition or formulation, or for a medicine for the inactivation of microorganisms, such as bacteria, fungi and / or viruses.

10. Use, according to claim 9, characterized by the viruses being respiratory viruses, such as enveloped viruses, like influenza, herpes, monkeypox (MPX), RSV and / or coronaviruses, like SARS-CoV-2.

11. Antiseptic, healing and / or inactivation method for microorganisms, such as bacteria, fungi and / or viruses, characterized by comprising the application of at least one compound as defined in any of claims 1 to 5 or at least one composition as defined in claim 6 or 7 or a formulation as defined in claim 8 to an individual or animal in a pharmaceutically effective quantity.

12. Method, according to claim 11, characterized in that the viruses are respiratory viruses, such as enveloped viruses, such as influenza, herpes, monkeypox (MPX), RSV and / or coronaviruses, such as SARS-CoV-2. Petition 870250076037, dated 08 / 27 / 2025, pp. 21 / 26

Images